Key result
Elevated creatinine, BUN, BNP, and decreased platelets and PaO2 predict adverse Type 2 CRS outcomes.
Why the study?
Despite the high morbidity and mortality of type 2 cardiorenal syndrome, robust diagnostic tools and prognostic models to guide clinical management are lacking.
Observational (n=519)
Yes
Elevated serum creatinine, BUN, BNP, and decreased platelet count and PaO2 are independent predictors of adverse outcomes in patients with Type 2 cardiorenal syndrome, which can be used to guide clinical management.
These biomarkers were associated with adverse outcomes in CRS-2; supports nomogram development but leaves open prospective validation before clinical use.
BACKGROUND: Type 2 CRS is characterized by the development of renal dysfunction secondary to chronic cardiac disease. Despite its high morbidity and mortality, there is a lack of robust diagnostic tools and prognostic models to guide clinical management. METHODS: This multicenter retrospective study included patients diagnosed with CRS type 2 based on the 2019 American Heart Association definition. Data were collected from electronic medical records of three hospitals between January 2021 and December 2023. Advanced statistical methods, including receiver operating characteristic (ROC) curve analysis, univariate Kaplan-Meier (KM) analysis, and multivariable Cox proportional hazards regression, were utilized to develop a nomogram for predicting patient prognosis. RESULTS: The study included 519 patients with CRS-2. Independent predictors of adverse outcomes included elevated serum creatinine and blood urea nitrogen (BUN) levels, decreased platelet count, elevated B-type natriuretic peptide (BNP), and decreased oxygen partial pressure (PaO2). These findings suggest that close monitoring of these markers is essential in clinical practice to identify patients at high risk of adverse events early on. CONCLUSION: Our study provides evidence that serum creatinine, BUN, platelet count, BNP, and PaO2 are independent predictors of adverse outcomes in patients with Type 2 CRS.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted an observational in Cardiorenal syndrome type 2 (n=519). Serum creatinine, BUN, platelet count, BNP, and PaO2 was evaluated on Adverse outcomes. Elevated serum creatinine, BUN, and BNP, and decreased platelet count and PaO2 were independent predictors of adverse outcomes in patients with Type 2 cardiorenal syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: